Translation deregulation in B-cell lymphomas

B-cell lymphomas are a heterogeneous group of diseases that can arise at different stages of B-cell development, often as a result of errors in the cells' unique ontogeny. Common oncogenic features are often observed, including chromosomal rearrangements, somatic mutations and transcriptional change. Disruption of translation regulation is also frequently implicated in both B-cell lymphoma development and progression. Deregulation of translation in lymphomagenesis can arise through changes to the proteins constituting the translational machinery or to their regulators, and to changes in miRNA (microRNA) expression. Abbreviations: BL, Burkitt's lymphoma; DLBCL, diffuse large B-cell lymphoma; eIF, eukaryotic initiation factor; 4E-BP, eIF4E-binding protein; FL, follicular lymphoma; HL, Hodgkin's lymphoma; IRES, internal ribosomal entry segment; ITAF, IRES trans-activating factor; MCL, mantle cell lymphoma; MCT-1, multiple copies in T-cell malignancies-1; miRNA, microRNA; mTOR, mammalian target of rapamycin; mTORC, mTOR complex; NHL, non-Hodgkin's lymphoma; PI3K, phosphoinositide 3-kinase; RISC, RNA-induced silencing complex; rpS6, ribosomal protein S6; UTR, untranslated region